Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen Berenson
AddedFeb 13, 2024
UpdatedMay 31, 2026
Stephen Berenson

Stephen Berenson

Board Member, Seres Therapeutics

CrunchbaseLinkedInThe Org

Stephen Berenson's Career

Seres Therapeutics
Seres Therapeutics

Cambridge, MA, US

Board Member· Board
Moderna
Moderna

Cambridge, MA, US

Board Member· Board
Cibo Technologies
Cibo Technologies

Cambridge, MA, US

Board Member· Board
Cellarity
Cellarity

Somerville, MA, US

Board Member· Board
Repertoire Immune Medicines
Repertoire Immune Medicines

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen Berenson's Career

Seres Therapeutics
Seres Therapeutics
Public$537.8M4312010Cambridge, MA, US
Board Member· Board

Leadership at Seres Therapeutics

David BerryDavid BerryCo-Founder
Roger PomerantzRoger PomerantzBoard Member
Willard DereWillard DereBoard Member
Meryl ZausnerMeryl ZausnerBoard Member
Paul BiondiPaul BiondiBoard Member
Greg BeharGreg BeharBoard Member

Similar to Seres Therapeutics

Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30
Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
Solarea BioSolarea BioCambridge, MA, USBiotechnology, Therapeuticsest. 2017Solarea BioCambridge, MA, US · est. 2017

Solarea Bio, a Cambridge-based biotech firm, innovates microbiome solutions for global health issues.

Series B · $26.2M24
DermBiontDermBiontBoston, MA, USTherapeuticsest. 2017DermBiontBoston, MA, US · est. 2017

DermBiont: A leading precision dermatology firm, developing targeted therapeutics for skin health.

Series B · $108.5M47
Moderna
Moderna
Public$3B3.9k2010Cambridge, MA, US
Board Member· Board

Leadership at Moderna

Sandra HorningSandra HorningBoard Member
Bob LangerBob LangerCo-Founder
Elizabeth NabelElizabeth NabelBoard Member
Melissa J. MooreMelissa J. MooreBoard Member
Elizabeth E. TallettElizabeth E. TallettBoard Member
Moncef SlaouiMoncef SlaouiBoard Member
Cibo Technologies
Cibo Technologies
Series C$67.4M722015Cambridge, MA, US
Board Member· Board

Leadership at Cibo Technologies

Trisa ThompsonTrisa ThompsonBoard Member
Noubar AfeyanNoubar AfeyanBoard Member
Mark FuscoMark FuscoBoard Member
Bruno BassoBruno BassoFounder
Daniel RyanDaniel RyanCEO
Kyung-mo KangKyung-mo KangBoard Member
Cellarity
Cellarity
Series C$294M1652017Somerville, MA, US
Board Member· Board

Leadership at Cellarity

Avak KahvejianAvak KahvejianBoard Member
Nick PlugisNick PlugisCo-Founder
Ian EstepanIan EstepanBoard Member
Jim CollinsJim CollinsBoard Member
Fabrice ChouraquiFabrice ChouraquiCEO
Marcello DamianiMarcello DamianiBoard Member
Repertoire Immune Medicines
Repertoire Immune Medicines
Series B$257.3M1752015Cambridge, MA, US
Board Member· Board

Leadership at Repertoire Immune Medicines

Torben Straight NissenTorben Straight NissenCEO
Ewen CameronEwen CameronFounder
Doug ColeDoug ColeBoard Member

Similar to Repertoire Immune Medicines

INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
InimmuneInimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
Immunitas TherapeuticsImmunitas TherapeuticsWaltham, MA, USCancer Therapeuticsest. 2019Immunitas TherapeuticsWaltham, MA, US · est. 2019

US-based Immunitas advances immuno-oncology therapeutics through an integrated genomics platform.

Series B · $97M33
Ernexa TherapeuticsErnexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11

Stephen Berenson's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Stephen Berenson

Eric ShaffEric ShaffCEO · Seres TherapeuticsDavid ArkowitzDavid ArkowitzBoard Member · KinetaNick NaclerioNick NaclerioFounder · Illumina VenturesJ. Milton HarrisJ. Milton HarrisCo-Founder · Serina TherapeuticsKim KamdarKim KamdarBoard Member · Sera Prognostics